Sglt2 Inhibitor

In the United Kingdom, Germany and Spain, dapagliflozin with standard therapy is a cost-effective treatment for chronic kidney disease, according to data published in the Clinical Journal of the American Society of Nephrology.

Prescription rates of SGLT2 inhibitors and GLP-1 receptor agonists among adults with type 2 diabetes in the Veterans Health Administration varied by race, with white patients most likely to receive these medications.

Dapagliflozin reduces risk for worsening heart failure and cardiovascular death in adults with heart failure with mildly reduced or preserved ejection fraction, regardless of baseline HbA1c, according to findings from the DELIVER trial.

Despite having greater access to preventive care, Medicare Advantage beneficiaries had poorer intermediate health outcomes and were less likely to receive newer diabetes drug therapies compared with those with fee-for-service Medicare.

Among adults with type 2 diabetes, white men and white women and those seeing an endocrinologist receive more prescriptions for SGLT2 inhibitors and GLP-1 receptor agonists than Black adults and those seen only in primary care, data show.

Fewer than one in 10 adults with type 2 diabetes in the U.S. use SGLT2 inhibitors or GLP-1 receptor agonists, and only SGLT2 inhibitors have seen an increase in use over the last decade, according to study findings.

Starting SGLT2 inhibitors among older patients did not increase risk for skeletal fractures compared with the use of dipeptidyl peptidase inhibitors, according to this study.

For patients with type 2 diabetes, first-line SGLT2 inhibitors might be better than metformin when it comes to their cardiovascular health, according to results of a population-based cohort study.

The use of SGLT2 inhibitors with type 2 diabetes is associated with lower risks for end-stage renal disease and acute renal failure compared with DPP-IV inhibitor use, according to study findings from Hong Kong.